Abbott scored a CE mark for the third generation of its popular Freestyle Libre continuous glucose monitoring (CGM) system in 2020, and has since filed for FDA approval, but the company has stayed quiet on the potential timing of that approval. Still, we think it could very well be approved sometime this year.

The Freestyle Libre 3 technology provides continuous, real-time glucose readings automatically delivered to smartphones every minute. The sensor is about the size of a penny.

"Abbott won't stop innovating when there's room to raise the bar,” said Jared Watkin, senior vice president of Abbott's diabetes business, after the company received the CE mark. “We've done that again with FreeStyle Libre 3, the smallest sensor that delivers life-changing benefits and best-in-class accuracy. People living with diabetes are at the center of our design process, and we made our next-generation technology even more discreet for a better user experience to make managing diabetes as easy and seamless as possible."